Decibel Therapeutics Appoints New Chief Medical Officer and COO
BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced the appointment of Dr. Peter Weber as the company’s new Chief Medical Officer, as well as the promotion of Paula Cobb to Chief Operating Officer. Dr. Weber, an otolaryngologist at Boston University Medical Center specializing in otology/neurotology, brings experience as a clinician, a scientist and a hearing…
Read MorePharmaceutical Treatments for Hearing Loss, a Brief Q&A with Michael Su, Ph.D., CSO of Decibel Therapeutics
Hearing loss is a critical public health issue that carries a significant social and economic cost. Decibel Therapeutics, a biotechnology startup based in Boston, is pursuing a comprehensive approach to developing precision medications for hearing and balance. We talked with Decibel’s chief scientific officer, Michael Su, Ph.D., about that work. Su and his colleagues will…
Read More
Decibel Therapeutics and Cocoon Biotech Announce Research Collaboration
BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, has announced a research collaboration with Cocoon Biotech to apply Cocoon’s proprietary silk fibroin platform to the development of therapeutics for hearing and balance disorders. According to the announcement, the companies will jointly conduct research into drug formulations optimized for transtympanic delivery to the ear, and Decibel will…
Read More
Decibel Therapeutics Obtains Exclusive License to Develop and Commercialize ORC-13661 from Oricula Therapeutics
BOSTON & SEATTLE — Boston-based biotech firm, Decibel Therapeutics, announced this week that it has obtained “an exclusive, worldwide license to the development and commercialization of ORC-13661” from Oricula Therapeutics for the prevention of hearing loss and balance disorders due to the use of aminoglycoside antibiotics. As part of the agreement with Decibel, Oricula will…
Read More
Decibel Therapeutics Snags $55 Million Series C Financing for Hearing Drug Development
BOSTON, MASSACHUSETTS — Biotech startup, Decibel Therapeutics, announced that it has raised $55M in a Series C financing round. According to the announcement, all the existing investors–Third rock Ventures, GV, SR One and Regeneron Pharmaceuticals–participated in the financing round and were joined alongside new investors: Foresite Capital, Bessemer Trust, Schroder Adveq, SCubed Capital, Longevity, and…
Read More
Sound Pharmaceuticals Completes Clinical Trial Enrollment on Meniere’s Drug; GV Invests in Decibel Therapeutics
SEATTLE, WASHINGTON — Sound Pharmaceuticals, a Seattle-based biotech firm, announced late last month that it had completed enrollment on its first Ménière’s disease clinical trial. The clinical trial will use SPI-1005, an investigational new drug developed by the company that mimics and induces Glutathione Peroxidase (GPx), which has been shown to reduce the swelling or…
Read More
Startup Gets $52 Million Investment to Develop Drug Treatment for Hearing Loss
BOSTON, MASSACHUSETTS – Third Rock Ventures, a biotechnology-focused venture capital firm located in Boston, announced the launch of a new startup company with the sole purpose of treating hearing loss. The new company, Decibel Therapeutics, raised $52 million dollars in Series A funding for its launch, with investment from Third Rock Ventures and SR One—the venture capital arm of…
Read More